1. Is RA Treatment Addressing the Real Needs of Patients?

3. Introduction/Overview

4. Improvements in Disease Activity Score Associated With Quality of Life Improvements

5. Daily-Life Burdens With Arthritis

6. Unmet Needs: Flares

7. Unmet Needs: The Burden of Disease (Fatigue)

8. RA Treatment Goals in the 21th Century

9. Rieke Alten's "Rheuma School"

10. Findings From a Literature Review on RA and Physical Activity

11. RA Patient-Centric Approach to Care

12. Identifying the High-Risk Patient: Progression Associated With ACPA Positivity

13. Evolution of Ever More Effective RA Therapies

14. In Some Patients Dose Reduction May Result in Resumption of Disease Activity

15. The Concept of Immunological Tolerance in The Context of RA

16. Fast-Tracking Patients With High-Risk Early Rheumatoid Arthritis

17. Choosing The Right Pro-Inflammatory Target: Often a Matter of Empirical Testing

18. JAK Inhibitors in RA

19. JAK Inhibitors: Safety Considerations

20. Comparing Clinical Results of JAK 1 / 3 and JAK 1 / 2 Inhibitors

21. Biomarker Matrices: SWEFOT Results

22. The Future of Biomarkers in RA

23. Potential Role of Synovial Biopsy in RA Drug Development And Clinical Practice

24. Patient-Reported Outcomes Assessed in RA Clinical Trials (2012-2014)

25. RA-BEAM: PRO Improvement With Baricitinib

26. The RAPID3 Patient-Reported Outcomes Index

27. Summary and Conclusions

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)